Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-05-21

Clinical Trial Update: Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating EGb761 for Friedreich Ataxia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EGb761 (Ginkgo biloba extract)

Snippet

Sponsor: Ipsen | Conditions: Friedreich Ataxia | Phase 2 | Status: COMPLETED | Results posted: 2013-05-21